Investment Rating - The industry investment rating is cautious [6][9]. Core Insights - Spot thermal coal prices have slightly declined, with QHD 5500 remaining flat at Rmb678/t and CCI 5500 down 0.3% WoW to Rmb670/t [1][9]. - Coking coal prices have remained stable, with Liulin No. 4 mine-mouth price flat at Rmb615/t and FOR price unchanged at Rmb1,280/t [2][9]. - QHD inventory has increased by 11.2% WoW to 6.85 million tons, indicating a return to elevated levels [2][9]. - The average operating rate of independent coking plants in China has shown a decline from 81.3% in 2019 to 64.7% in 2024, but there are signs of a reversal in 2025 due to better steelmaking demand [3][4]. Summary by Sections Price Trends - Spot thermal coal prices have shown a slight decline, with NEWC price falling 2.1% WoW to US$94/t and QLD coking coal down 0.5% WoW to US$183/t [6]. - Mine-mouth prices for Shanxi Datong 5800 decreased by 2.3% WoW to Rmb548/t [1]. Inventory Levels - QHD port inventory increased by 11.2% WoW to 6.85 million tons, while inventory at Bohai Rim ports decreased by 0.9% WoW to 29.9 million tons [2][6]. Coking Coal Market - Coking coal prices have remained stable, with Liulin No. 4 mine-mouth price flat at Rmb615/t and FOR price unchanged at Rmb1,280/t [2][9]. - The average operating rate at independent coking plants has shown a decline over the past five years but is showing signs of recovery in 2025 [3][4].

Investment Rating - The industry view for China Materials is rated as Attractive [6] Core Insights - Cement is preferred due to supply discipline, price coordination, lower costs, and no impact from trade wars. The building materials sector is recovering from improved secondary property sales [1][2] - The cement industry is experiencing margin expansion and has formed new alliances to focus on profit rather than volume. A 5-10% year-over-year decline in demand is expected, but margin recovery is anticipated due to lower coal prices and effective supply control measures [2][3] - Late-cycle building materials are recovering, supported by better secondary home sales and government initiatives. However, demand remains soft due to declining property starts and completions [3] - The float glass segment is facing weak fundamentals, with low demand from property developers and high supply levels continuing to pressure earnings [4] Summary by Sections Cement - Major cement players have agreed to prioritize profit over market share, leading to a healthier price recovery despite weak property demand. The industry is expected to see a margin recovery due to lower coal prices and effective supply control policies [2] - Top producers like Conch, CNBM, and CR Cement are likely to benefit from new supply control measures aimed at reducing overproduction [2] Building Materials - The late-cycle building materials sector is expected to see mild growth in new infrastructure and industrial investments, with demand improving from better secondary home sales and government programs [3] - Companies such as Yuhong, Weixing, and Lesso are identified as potential beneficiaries of this recovery [3] Float Glass - The float glass market is currently weak, with low order days at processing plants and high supply levels continuing to exert pressure on earnings [4] Price Targets and Ratings - Price targets for key companies include Anhui Conch (A) at RMB 37.40 with a 47% upside, Anhui Conch (H) at HKD 29.80 with a 35% upside, and China Resources Building Materials at HKD 2.30 with a 39% upside [7][11] - Ratings for companies in the cement sector are predominantly Overweight (OW), while Xinyi Glass and Zhuzhou Kibing Glass are rated Underweight (UW) due to weak fundamentals [11][12]

Investment Rating - The report provides an "Attractive" industry view for the energy sector in Asia Pacific [7]. Core Insights - Asia (excluding China) is projected to increase energy imports from the US, with potential additional imports of US$51 billion annually by 2028, which would help lower energy costs and diversify supply [2][4]. - The report highlights that US energy exports to Asia could rise significantly, with crude oil, natural gas, propane, and ethane being the primary products [4][12][15]. - The increase in US energy imports is expected to reduce the trade surplus with the US by 11%, with countries like Japan, Indonesia, and India seeing reductions of 18-39% in their current surpluses [11]. Summary by Relevant Sections Energy Import Projections - Asia (ex-China) imported 40 exajoules (EJ) of energy in 2023, accounting for about one-third of its needs, with US imports making up approximately 9% of the region's US$600 billion energy imports in 2024 [4]. - The report estimates that if 30-35% of LNG imports are sourced from the US, energy imports could reach US$51 billion by 2028, and a 50% share would increase this to US$60 billion [4]. Country-Specific Import Data - India: Expected to increase imports from US$10 billion in 2023-24 to US$24 billion by 2028, a US$14 billion increment [5]. - Japan: Anticipated to double its imports from US$12 billion to US$24 billion [5]. - South Korea: Imports projected to rise from US$20 billion to US$26 billion [5]. - Indonesia: Expected to increase from US$1 billion to US$8 billion [5]. Product-Specific Insights - Crude Oil: Asia (ex-China) imported approximately 1.4 million barrels per day (mbpd) of US crude in 2023, with potential to increase by 1.5 mbpd by 2028, translating to over US$30 billion annually [12]. - LNG: Asia (ex-China) imported 26 million tons per annum (mntpa) in 2024, with potential to import 47 mntpa from the US by 2028, equating to US$12 billion annually [13]. - Propane: Asia imports 66 mntpa of propane annually, with US propane being 30% cheaper than Asian benchmarks, indicating a potential for increased imports from the US [15]. Beneficiaries of Increased Imports - Companies such as Reliance, GAIL, and Tokyo Gas are expected to benefit from the increased US energy imports due to lower costs [14][5].

Investment Rating - The report assigns a Neutral investment rating for Goertek [1][17][18] Core Insights - Goertek is recognized as the global leading assembler for VR headsets, with expectations of a year-over-year revenue decline in 2025, followed by growth resuming in 2026 due to anticipated market share growth for new AirPods [11][17] - The revenue and earnings compound annual growth rates (CAGRs) are projected at 6% and 18% respectively for the period from 2024 to 2027, driven more by improved cost structure than top-line growth [11][17] - The earnings contribution from AR/AI glass is expected to be limited [11][17] Financial Estimates - Adjusted EPS for FY25 is revised down from Rmb0.95 to Rmb0.89, and for FY26 from Rmb1.11 to Rmb1.08 [2] - Quarterly forecasts for FY25 show Q1 at Rmb0.13, Q2 at Rmb0.16, Q3 at Rmb0.33, and Q4 at Rmb0.26, leading to an annual adjusted EPS of Rmb0.89 [3] - Revenue estimates for FY25 are adjusted to Rmb94,474 million, down from Rmb99,125 million, reflecting a 5% decrease [15] Valuation - The price target for June 2026 is set at Rmb22.50, based on a 19x one-year forward P/E, aligning with the average of peers [12][18] - The current market cap is approximately $9,959 million, with a share price of Rmb20.83 as of April 22, 2025 [10] Performance Metrics - Year-to-date performance shows a decline of 19.3%, with a 12-month performance increase of 39.8% [10] - The adjusted net income for FY25 is projected at Rmb3,090 million, with a net margin of 3.3% [21]

Investment Rating - The report does not explicitly state an investment rating for the industry [1]. Core Insights - The US interest rates market shows a significant decline in yields across various maturities, with the 2-year yield dropping by 14.9 basis points to 3.794% and the 10-year yield decreasing by 6.7 basis points to 4.326% [4]. - The spread between different maturities has also changed, with the 2s/10s spread narrowing by 52.6 basis points [4]. - The report highlights a notable performance in the mortgage-backed securities market, with FNMA 3.5% coupon bonds trading at 88-296, reflecting a performance change of 0-13+ [4]. Summary by Sections General Market Summary - The report provides a comprehensive overview of the US interest rates market, detailing changes in yields and spreads across various maturities [3]. Treasury Yields - The 2-year yield is at 3.794%, down 14.9 basis points; the 5-year yield is at 3.934%, down 16.2 basis points; and the 30-year yield is at 4.809%, up 2.4 basis points [4]. Spread Analysis - The report indicates a significant narrowing of spreads, with the 2s/10s spread decreasing by 52.6 basis points, reflecting market adjustments [4]. Mortgage Performance - The FNMA 3.5% coupon bonds are highlighted with a trading price of 88-296, indicating a performance change of 0-13+ [4]. Market Data - The report includes various market data points, such as the S&P 500 closing at 5,282.70, and the USD/JPY exchange rate at 142.410 [4].

Investment Rating - The report initiates coverage of Aier Eye with a Neutral (N) rating and a price target (PT) of Rmb13.00 for December 2025 [1][4][32]. Core Insights - Aier Eye is positioned as a leader in the expanding ophthalmology market, driven by an aging population and increasing quality of life demands. The company benefits from resilient demand for cataract and eye disease therapies, ensuring steady industry growth despite a sluggish consumer economy in China [1][8][36]. - The report estimates an 18% compound annual growth rate (CAGR) for earnings per share (EPS) from 2024 to 2027, but notes that the stock is reasonably priced at a 28x FY25E price-to-earnings (PE) ratio, suggesting a wait for a pullback or signs of recovery in discretionary procedures [1][8][32]. Market Overview - The ophthalmic services market in China is projected to grow from Rmb73 billion in 2015 to Rmb286 billion by 2030, with an annual growth rate of approximately 11% [5][37]. - The demand for age-related conditions, particularly cataracts affecting around 150 million patients, and a large base of over 700 million myopic patients, is expected to drive growth in refractive surgery and medical optometry services [5][38]. Company Positioning - Aier Eye operates over 900 hospitals and clinics, holding approximately 8% of the total market share, and is expected to achieve a gross margin of 50% by 2024, which is 5-10% higher than its peers [5][17]. - The company’s physician partnership model and equity incentive programs are crucial for talent retention and clinical innovation, which are essential for maintaining service quality [5][8]. Financial Projections - Revenue is expected to grow from Rmb20.37 billion in FY23 to Rmb27.18 billion in FY26, with an adjusted EBITDA margin projected to stabilize around 32% [7][8]. - The report forecasts a 25% revenue growth for high-margin refractive surgery from FY25 to FY27, although growth in this segment is expected to be flat in FY24 [5][8]. Valuation - The price target of Rmb13.00 is based on a discounted cash flow (DCF) valuation, assuming a market risk premium of 6.2% and a risk-free rate of 3.8% [9][32]. - Aier Eye's valuation is considered reasonable compared to its peers, with a forward-looking PE ratio of 28x, which is in line with the average PE of comparable private specialty hospitals [23][28].

Investment Rating - The report maintains a "Neutral" rating for the company [2][11][15]. Core Insights - The company reported Q1 2025 revenue of 6.3 billion yuan, a year-on-year increase of 1% but a quarter-on-quarter decrease of 36%. Net profit was 653 million yuan, showing a year-on-year increase of 16% and a quarter-on-quarter increase of 81% [11][15]. - The long-term outlook anticipates a gradual recovery in government projects, increased corporate demand, expansion of innovative businesses, and growth in overseas markets. However, concerns regarding profitability may persist [11][15]. - The projected compound annual growth rates for revenue and profit from 2025 to 2027 are 8% and 24%, respectively [11][15]. Summary by Sections Financial Forecasts - Revenue projections for FY 2025 are 33.67 billion yuan, with adjusted net profit expected to be 3.09 billion yuan and adjusted earnings per share at 0.94 yuan [10][18]. - The company is expected to achieve a revenue growth rate of 4.6% in 2025, with a net profit margin of 9.2% [10][18]. Valuation - The target price of 17.5 yuan is based on a 12x forward P/E ratio, which is approximately one standard deviation below historical valuations [12][16]. - The adjusted earnings per share for FY 2026 is projected to be 1.31 yuan, with a further increase to 1.66 yuan in FY 2027 [10][18]. Stock Performance - The stock has shown a year-to-date performance of -1.3%, with a 12-month performance of -8.7% [8]. - The stock price as of April 21, 2025, was 15.79 yuan, with a target price of 17.50 yuan set for June 2026 [3][12].

Investment Rating - The report assigns an "Overweight" (OW) rating to General Motors (GM) and Ford, while Tesla and Rivian are rated "Underweight" (UW) [6][7]. Core Insights - The automotive industry is experiencing varied performance metrics across different companies, with GM and Ford showing potential upside in their stock prices, while Tesla and Rivian face significant downside risks [6][7]. - The report highlights the importance of valuation metrics such as EV/EBITDA, P/E ratios, and sales growth projections for assessing investment opportunities within the automotive sector [6][22]. Global Auto OEMs Investment Comparables - General Motors (GM) has a current price of $44.57 with a market cap of $43.067 billion and a target price of $53.00, indicating a 19% upside potential [6]. - Ford (F) is priced at $9.63 with a market cap of $38.294 billion and a target price of $11.00, representing a 14% upside [6]. - Ferrari (RACE) is valued at $439.97 with a target price of $460.00, showing a 5% upside [6]. - Tesla (TSLA) is currently priced at $241.37 with a target price of $120.00, indicating a -50% downside [6]. - Rivian (RIVN) has a price of $11.60 with a target price of $11.00, reflecting a -5% downside [6]. Global Auto Parts Suppliers Valuation Metrics - The average EV/EBITDA for US auto parts suppliers is projected at 1.8x for 2024, with a corresponding EBITDA margin of 12% [22]. - Aptiv (APTV) is rated "Overweight" with a current price of $51.71 and a target price of $102, indicating a 97% upside [22]. - Borg Warner (BWA) is rated "Overweight" with a price of $26.45 and a target price of $46, representing a 74% upside [22]. - Lear Corp (LEA) is rated "Overweight" with a price of $79.42 and a target price of $140, indicating a 76% upside [22]. Performance Metrics - The report indicates that the average revenue CAGR for US auto parts suppliers is projected to be 2% from 2023 to 2025 [74]. - The EBITDA margin for US auto parts suppliers is expected to be around 12% in 2025, with some companies showing higher margins [74][83]. - The report also highlights the financial returns of various suppliers, with some companies achieving significant returns on invested capital (ROIC) [54][56].

Investment Rating - The report maintains a trading range for the S&P 500 between 5000-5500, indicating a cautious outlook on the market [4][6][11] Core Insights - The dispersion of earnings per share (EPS) revisions is increasing, suggesting that the upcoming earnings season may act as a rotational catalyst rather than affecting the index level [4][25] - The report emphasizes the importance of identifying high-quality stocks in industries that are less risky, such as Transports, Materials, Pharma/Biotech, and Tech Hardware [4][25] - There is a notable uncertainty surrounding tariff impacts, with many companies withdrawing guidance or adopting conservative approaches due to macroeconomic uncertainties [24][41] Summary by Sections Market Overview - The S&P 500 is expected to remain within the 5000-5500 range due to competing factors affecting both upside and downside risks [4][6] - Upside risks include a more dovish Federal Reserve, a broader trade deal with China, and improved earnings revisions, while downside risks involve declining business confidence and rising back-end rates [4][11] Earnings Revisions - Earnings revisions breadth is currently at -24%, the lowest since the 2022 growth scare, indicating a potential for further cuts to 2025/2026 EPS [41][42] - Cyclical and tariff-sensitive industries, such as Autos, Transports, and Tech Hardware, are leading the downward revisions [41][46] Sector Analysis - In Hardlines/Broadlines/Food Retail, companies are reducing exposure to China and absorbing about 50% of tariff costs, with no significant consumer slowdown observed [34] - The Tech Hardware sector is facing challenges due to tariffs, with enterprise spending remaining robust while small and medium businesses are delaying projects [37] - The Media & Telecom sector is experiencing weaker advertising spending, with companies adjusting guidance downward due to macro uncertainties [37] Investment Opportunities - The report suggests focusing on high-quality stocks in less risky industries, utilizing tools such as industry frameworks and quality stock screens to identify potential investments [4][25] - Specific companies identified as quality cyclicals include Halliburton, Schlumberger, and Ecolab, among others [47]

Investment Rating - The report initiates coverage of Topchoice with an Underweight (UW) rating and a price target (PT) of Rmb34 for December 2025 [1][8][23]. Core Insights - The dental services industry in China is facing both short- and long-term challenges, leading to profitability pressure for Topchoice. The company's earnings per share (EPS) estimates for FY25 and FY26 are projected to be 8% and 10% below consensus, respectively [1][8][21]. - Topchoice's revenue is heavily reliant on Zhejiang Province, which accounts for 90% of its total revenue, raising concerns about geographical concentration and expansion momentum [5][8][21]. - The report highlights that the dental services market is fragmented, with only about 3% of dental institutions operating as chains, limiting pricing power and growth potential [5][28][33]. Summary by Sections Company Overview - Topchoice operates 84 medical facilities and has approximately 3,100 dental chairs as of Q3 FY24 [1][8]. - The company has seen flat revenue growth from FY21 to FY24E, with a projected compound annual growth rate (CAGR) of 10% from FY24 to FY27 [5][8]. Financial Performance - Revenue for FY23 was Rmb2,847 million, with projections of Rmb2,938 million for FY24 and Rmb3,125 million for FY25 [7]. - The adjusted net income for FY25 is estimated at Rmb538 million, reflecting a growth of 7% from FY24 [7]. Market Dynamics - The dental services market in China is projected to grow at a CAGR of 7% from 2024 to 2028, reaching Rmb193 billion, but has faced fluctuations in revenue growth due to the pandemic and economic conditions [30][28]. - The report notes that the average price of dental implants has decreased significantly due to government-led procurement policies, but the expected increase in demand has not materialized as anticipated [45][50]. Valuation - The report uses a discounted cash flow (DCF) model to arrive at the price target of Rmb34, assuming a weighted average cost of capital (WACC) of 12% and a terminal growth rate of 2.5% [9][23][25]. - Topchoice's current P/E ratio of 35.5x for FY25 is considered a premium compared to peers, which raises concerns about the sustainability of such valuations given the company's growth outlook [21][8]. Risks and Challenges - The report identifies several risks, including the company's reliance on a single geographic region, challenges in expanding outside Zhejiang, and the competitive landscape of the dental services market [5][21][28]. - The orthodontics segment is also under pressure, with declining treatment volumes and a shift towards more cost-effective options among consumers [54][61].